Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Salipro Biotech Obtains Granted Patents in the United States and China for Direct Extraction of Membrane Proteins and Library Generation

Salipro Biotech strengthens its IP portfolio protecting its innovative, proprietary technology to enable the development of therapeutics against challenging drug targets, including GPCR’s, SLCs and Ion Channels. Stockholm, Sweden, September 07, 2022 – Salipro Biotech AB, a Swedish biotech company with a leading technology platform for the stabilization of membrane proteins for drug development, announced today that its patent entitled “Saposin lipoprotein particles and libraries from crude membranes” has been issued by both the U.S. Patent and Trademark Office (U.S. Patent No. 11,346,843B2)

Nordea Economic Outlook: Feeling the Squeeze

The energy crisis has hit the European economy hard, and the risk of a recession in the Euro area is real. Inflation has reached the highest level since the early 1980s, and central banks seem determined to fight it through aggressive monetary policy. This is also the case in the Nordic countries where housing markets face a sharp slowdown, says Helge Pedersen, Nordea Group Chief Economist.   The Nordic economies have recovered strongly from the pandemic but are now being hit by the sharp increase in cost of living and the uncertain economic environment. The common denominator for the

Lena Philipsson to star in Viaplay’s ‘The Street Where I Live’

· Six-part drama inspired by hit song from one of Sweden’s leading musical artists · ‘The Street Where I Live’ created and scripted by Mikael Newihl (‘Max Anger’) at Viaplay Studios, with Viaplay Content Distribution handling global sales · Viaplay to premiere at least 70 Originals in 2022 Lena Philipsson, one of Sweden’s most successful musical artists, will take on her first lead drama role in the Viaplay Original ‘The Street Where I Live’. Philipsson has had no fewer than 13 albums in the country’s top 20-chart since her debut in 1984, and represented Sweden in the 2004

Salipro Biotech Obtains Granted Patents in the United States and China for Direct Extraction of Membrane Proteins and Library Generation

Salipro Biotech strengthens its IP portfolio protecting its innovative, proprietary technology to enable the development of therapeutics against challenging drug targets, including GPCR’s, SLCs and Ion Channels.Stockholm, Sweden, September 07, 2022. – Salipro Biotech AB, a Swedish biotech company with a leading technology platform for the stabilization of membrane proteins for drug development, announced today that its patent entitled “Saposin lipoprotein particles and libraries from crude membranes” has been issued by both the U.S. Patent and Trademark Office (U.S. Patent No. 11,346,843B2)

Fidesmo partners with Infineon for accessibility of services to secure elements

Swedish company Fidesmo expands its partner network in Europe by joining forces with Infineon Technologie AG, a leading secure element manufacturer providing connectivity and security in the field of IoT, mobility and payments . The two companies now look to grow the availability of contactless services for Infineon’s secure elements. The partnership has already begun with creating a more flexible solution for payment wearables with more areas of cooperation to be explored.Fidesmo is specialized in providing scalable integrations between services and hardware manufacturers. Together with

Investment AB Latour has completed repurchase of shares

Investment AB Latour (publ) has on September 6, 2022, repurchased 100,000 class B shares (ISIN SE0010100958) for a price of SEK 205.80 per share. Latour's holding of own shares after the repurchase amounts to 514,900 class B shares. The total number of outstanding shares in the company is 639,325,100. The repurchase was completed on Nasdaq Stockholm by SEB on behalf of Latour. The purpose of the repurchase is to secure Latour's commitments to deliver shares in accordance with Latour's call option program. Göteborg, September 7, 2022 INVESTMENT AB LATOUR (PUBL)Johan Hjertonsson, CEO

CS MEDICA announces that their 6 CANNANSEN®CBD Medical Products has been successfully registered at MHRA for Sales in United Kingdom.

CS MEDICA A/S (”CS MEDICA” or the ”Company”) announces today that their 6 CANNANSEN® CBD Medical Products has been successfully registered at Medicines and Healthcare products Regulatory Agency ("MHRA") in United Kingdom. The 6 CANNANSEN® CBD Medical Products has been through a registration procedure at MHRA – the process is finalized and the products are now ready for Sale in United Kingdom.The registration of the 6 CANNANSEN® CBD medicinal products with the MHRA enables CS MEDICA to market and sell their 6 CANNANSEN® CBD medicinal products in the UK. The registration has further

BioStock: Swedish Hockey League taking concussion treatment seriously

Concussions are a serious, yet too often, underestimated issue in ice hockey. However, over the last few years, the Swedish Hockey League has been taking steps to give this problem more attention in the name of player safety, including the adoption of PolarCool’s concussion treatment PolarCap. BioStock reached out to IF Malmö Redhawks defenseman Markus Lauridsen to get a player’s perspective on the handling of concussions by the league and why PolarCap could be a gamechanger.Read the interview with Markus Lauridsen at biostock.se: Swedish Hockey League taking concussion treatment

2020 Bulkers Ltd. (2020) – Commercial update and key information relating to the cash distribution for August 2022

Oslo, Norway, September 7, 2022 Commercial update: In August 2022, the Company achieved average time charter equivalent earnings of approximately US$21,800 per day, gross. The Company’s six vessels trading on index-linked time charter earned approximately US$16,700 per day, gross, including average daily scrubber benefits of approximately US$4,000 per day. The Company’s two vessels trading on fixed time charter earned approximately US$37,000 per day, gross, including average daily scrubber benefits of approximately US$5,300 per day. The Baltic 5TC Capesize Index averaged US$9,339

Alzinova announces new positive safety review of its Phase 1b study in Alzheimer’s disease

Alzinova AB (publ) (“Alzinova” or “the Company”), announces today that a second external safety review has been carried out of the Company's clinical phase 1b study - with a positive assessment to continue the study as planned. Behind the review is an independent expert group, Data and Safety Monitoring Board ("DSMB"), which continuously reviews the study. Based on the patients included in the study, the DSMB recommends continuing the study as planned without adjustments. The Company has previously communicated DSMB’s first review in April 2022, which also gave the green light to continue the

Corem divests properties in Borås, Lerum and Gothenburg for SEK 200 million

Corem has signed contracts to divest seven properties for a total underlying property value of SEK 200 million. The properties, which are situated in Borås, Lerum and Gothenburg, have a lettable area of approximately 27,900 sq.m. and primarily consist of industry/warehouse, wellness and retail premises. The rental value amounts to SEK 19 million and the economic occupancy rate amounts to 86 per cent.”These divestments are an additional step in the streamlining of Corem at the same time as we free up capital for other investments in more prioritized segments”, says Peeter Kinnunen, Head of

Lytix Biopharma announces approval to expand the ATLAS-IT-05 study to Europe

Oslo, 7 September 2022. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company, today announces the regulatory approval from European authorities to commence the ATLAS-IT-05 study in three European countries.ATLAS-IT-05 is a Phase II combination study evaluating LTX-315 and pembrolizumab in patients with advanced melanoma. The study was initiated at MD Anderson Cancer Center in 2021 and is currently ongoing in the US. The objective of the study is to document whether LTX-315 in combination with pembrolizumab is effective in inducing responses in

Africa Energy Announces Block 11B/12B Operations Update

VANCOUVER, BC, September 7, 2022 /CNW/ – Africa Energy Corp. (TSX Venture: AFE) (Nasdaq First North: AEC) (“Africa Energy” or the “Company”), an oil and gas company with exploration assets offshore South Africa and Namibia, is pleased to announce that the joint venture partners on Block 11B/12B offshore South Africa (the “Partnership”) have submitted an application for a Production Right. The Partnership is relinquishing the northern portion of the block and electing to enter a Gas Market Development Period to confirm the economic viability of the project.   Garrett Soden, the Company’

Sunnybrook Health Sciences Centre in Canada selects RayStation

RaySearch Laboratories AB (publ) announces that Sunnybrook Health Sciences Centre – Odette Cancer Centre in Toronto, Canada, has placed an order for RayStation®* treatment planning system.Sunnybrook Health Sciences Centre, one of Canada’s largest hospitals, offers a highly specialized comprehensive cancer program and treats more than 7,000 cancer patients per year. The center is equipped with 13 linear accelerators. This is the first sale made in Ontario since a Master Purchase Agreement was signed with Ontario Health in the first quarter of 2022. The agreement includes a complete

NCC issues green corporate bonds

NCC is providing the capital market with a further opportunity to invest in green projects by issuing green bonds with a total value of SEK 1 billion. Bonds valued at SEK 1 billion with a three-year maturity were issued on September 1, with September 8, 2022 as the settlement date. “As with our previous issue, interest has been significant, which is gratifying and demonstrates the confidence of the capital market in NCC’s financial strength. We have a clear ambition for our sustainability initiatives, and integrating this into our financing strategy is a clear example of what I

TikoMed’s drug candidate ILB® inhibited infection of human cells by Dengue, Zika and Yellow Fever viruses in vitro, providing further support for its broad spectrum mechanism of action

Viken, Sweden – 7[th] September 2022 – TikoMed today announced the inclusion in bioRxiv* of an in vitro study examining the ability of the company’s lead drug candidate ILB® to inhibit infection of human cells by four serotypes of Dengue virus (DENV1-4), two strains of Zika virus (African and Asian) and Yellow Fever virus (vaccine strain YF17D) assessed by immunofluorescence of viral particles. In the study, ILB® potently inhibited infection by all the strains of Dengue, Zika and Yellow Fever virus in a concentration-dependent manner with IC50 for ILB® ranging from 31 to 343 μg/ml.

Minesto starts commissioning of second “Dragon 4” tidal energy power plant

The second Dragon Class tidal energy power plant “Dragon 4” has now arrived at Minesto’s grid-connected site in Vestmanna, Faroe Islands. This power plant commissioning has now commenced, and it will greatly benefit from previous configuration testing executed with the first unit.“As we are now commissioning the second “Dragon 4” unit, it’s with vital experience of cost-efficient onshore and offshore operations. In Vestmanna, we have created a flexible setup, where a small team can assemble and launch the kite in a few hours, practically in all tidal conditions.  This operating methodology

Herantis Pharma to Participate in the Nordic Life Science Days, Sweden

Herantis Pharma Plc, Press Release, 7 August 2022 at 09:00 EEST   Herantis Pharma Plc (“Herantis”), developing disease modifying therapies for Parkinson’s disease, today announced that CEO Antti Vuolanto and CFO Tone Kvåle will be presenting and holding 1x1 meetings at the Nordic Life Science Days (NLS) in Malmö, Sweden on September 28-29, 2022. Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life science industry.   Presentation Time: September 28, 11:12 a.m. EEST / 10:12 a.m. CEST   The presentations will be accessible to event

Finnair introduces new strategy to return to profitability

Finnair Plc           Stock Exchange Release           7 September 2022 at 9.00 a.m. EEST Finnair’s strategy has long been based on connecting Europe and Asia via the short northern route, using Russian air space. Following Russia’s invasion of Ukraine and the subsequent closure of Russian air space, flight times to Finnair’s Asian destinations are now considerably longer, weakening the profitability of the company. Finnair’s new strategy aims to return to profitability regardless of closed Russian air space. As Finnair is now faced with a different competitive situation and the

AnaCardio raises SEK 150 million to advance drug candidate AC01 in heart failure

STOCKHOLM, SWEDEN - 7 September 2022: AnaCardio announced today the completion of a SEK 150 M Series A financing round, co-led by Flerie Invest AB (Flerie) and Industrifonden. 3B Future Health Fund (3BFHF) joined Flerie and Industrifonden to complete the round together with the founding investor Karolinska Development AB and current investors Fredrik and Ann-Helene Ljungström. Founded based on ground-breaking research encompassing pre-clinical and clinical discovery of a novel mode of action in the cardiovascular and heart failure setting by Professor Lars Lund, Professor of Cardiology

Statement by the independent bid committee of Cary Group Holding AB (publ) in relation to the increased public cash offer by Teniralc BidCo AB of SEK 70 per share

The independent bid committee of Cary Group Holding AB (publ) (“Cary Group or the “Company”) unanimously recommends that all shareholders accept the increased offer by Teniralc BidCo AB (“Teniralc”).This statement is made by the independent bid committee of Cary Group pursuant to Section II.19 of Nasdaq Stockholm’s Takeover Rules (the “Takeover Rules”). Background On 29 June 2022, CVC Funds and Nordic Capital, through Teniralc, announced a public cash offer to the shareholders of Cary Group to tender any and all shares in Cary Group to Teniralc at a price of SEK 65 in cash per share (

NCC’s safety initiatives reducing the number of accidents

Since 2018, the number of serious accidents and incidents has fallen by 38 percent at NCC, clearly demonstrating that the Group’s systematic safety initiatives have yielded results. For the twelfth consecutive year, Awareness Day is being organized today at all of NCC’s workplaces to shine the spotlight on health and safety. Image: "Time Out” is a method that encourages employees to down tools when they experience unsafe situations. At 9:00 a.m. on the first Wednesday in September, work at all of NCC’s workplaces in the Nordic region will break for the Group’s annual Awareness

Aqilion has completed a rights issue

AQILION AB (publ) announces today that the company has completed a rights issue with preferential rights for existing shareholders. The company will thus receive SEK 30.5 million after issue costs. The rights issue was carried out as an issue of units. Each unit contains four (4) shares and two (2) warrants of the subscription series TO1. In addition to the initial issue, the company may, subject to full exercise of share warrants of series TO1, receive an additional amount of approximately SEK 20.2 million. Share warrants of series TO1 have an exercise period February - March 2023.

CapMan announces new strategy and updated long-term financial objectives – raises growth objective and maintains dividend policy unchanged

CapMan Plc Stock Exchange Release / Other information disclosed according to the rules of the Exchange 7 September 2022 at 8:30 a.m. EEST CapMan announces new strategy and updated long-term financial objectives – raises growth objective and maintains dividend policy unchanged CapMan announces its new strategy and updates its long-term financial objectives. CapMan’s vision is to be the most responsible Nordic private assets company. The company’s strategic objective is to double its assets under management to EUR 10 billion over the next five years. Following the updated strategy,

There are no items matching the current filter
There are no more items matching the current filter
Back to top